title: Effect of moxifloxacin on production of proinflammatory cytokines from human peripheral blood mononuclear cells.
abstract: The effects of moxifloxacin, a new methoxyfluoroquinolone, on the production of proinflammatory cytokines from human peripheral blood mononuclear cells (PBMCs) were evaluated. Moxifloxacin inhibited the production of tumor necrosis factor alpha (TNF-alpha) and/or interleukin-6 (IL-6) by PBMCs stimulated with lipopolysaccharide (LPS), lipoteichoic acid (LTA), and heat-killed bacteria in a concentration-dependent manner without cytotoxic effects. The addition of moxifloxacin reduced the population of cells positive for CD-14 and TNF-alpha and for CD-14 and IL-6 among the LPS- or LTA-stimulated PBMCs. By Western blot analysis, moxifloxacin pretreatment reduced the degradation of IkappaBalpha in LPS-stimulated PBMCs. In conclusion, moxifloxacin could interfere with NF-kappaB activation by inhibiting the degradation of IkappaBalpha and reduce the levels of production of proinflammatory cytokines.
authors.affiliation: Division of Infectious Disease, Department of Internal Medicine, College of Medicine, Catholic University of Korea, Seoul, Korea.
authors.forename: Jung-Hyun
authors.initials: JH
authors.lastname: Choi
authors.forename: Min-Jin
authors.initials: MJ
authors.lastname: Song
authors.forename: Seung-Han
authors.initials: SH
authors.lastname: Kim
authors.forename: Su-Mi
authors.initials: SM
authors.lastname: Choi
authors.forename: Dong-Gun
authors.initials: DG
authors.lastname: Lee
authors.forename: Jin-Hong
authors.initials: JH
authors.lastname: Yoo
authors.forename: Wan-Shik
authors.initials: WS
authors.lastname: Shin
mesh_terms: D000276:Adjuvants, Immunologic / Q000494:pharmacology; D000890:Anti-Infective Agents / Q000494:pharmacology*; D001372:Aza Compounds / Q000494:pharmacology*; D015153:Blotting, Western; D002443:Ceftriaxone / Q000494:pharmacology; D002470:Cell Survival; D002511:Cephalosporins / Q000494:pharmacology; D016207:Cytokines / Q000096:biosynthesis*; D004797:Enzyme-Linked Immunosorbent Assay; D004926:Escherichia coli / Q000276:immunology; D005434:Flow Cytometry; D024841:Fluoroquinolones; D006801:Humans; D020672:I-kappa B Proteins / Q000378:metabolism; D066298:In Vitro Techniques; D015850:Interleukin-6 / Q000096:biosynthesis; D018950:Lipopolysaccharide Receptors / Q000378:metabolism; D009000:Monocytes / Q000187:drug effects* / Q000378:metabolism*; D000077266:Moxifloxacin; D015242:Ofloxacin / Q000494:pharmacology; D011804:Quinolines / Q000494:pharmacology*; D013296:Streptococcus pneumoniae / Q000276:immunology; D014409:Tumor Necrosis Factor-alpha / Q000096:biosynthesis
chemical_list: D000276:Adjuvants, Immunologic; D000890:Anti-Infective Agents; D001372:Aza Compounds; D002511:Cephalosporins; D016207:Cytokines; D024841:Fluoroquinolones; D020672:I-kappa B Proteins; D015850:Interleukin-6; D018950:Lipopolysaccharide Receptors; D011804:Quinolines; D014409:Tumor Necrosis Factor-alpha; D002443:Ceftriaxone; D015242:Ofloxacin; D000077266:Moxifloxacin